Personal genetics company 23andMe announced Tuesday its intention to voluntarily delist its shares from the Nasdaq stock market. In addition to delisting, the company plans to deregister its securities with the U.S. Securities and Exchange Commission (SEC). This decision marks a notable change for the company, which went public via a SPAC merger in 2021.
The announcement did not provide specific details regarding the rationale behind the delisting and deregistration. Companies may choose to delist for a variety of reasons, including cost savings, reduced regulatory burdens, or strategic shifts in business focus. Further information is expected to be released by 23andMe in the coming days.
Investors and industry analysts are closely watching 23andMe's next steps to understand the long-term implications of this move. The company's future direction and any potential restructuring plans remain uncertain.
23andMe Announces Plans to Delist from Nasdaq
Genetic testing company 23andMe revealed plans Tuesday to voluntarily remove its stock listing from the Nasdaq stock exchange. The company also intends to deregister its securities with the U.S. Securities and Exchange Commission (SEC). This move signals a significant shift in 23andMe's strategy. The reasons behind this decision were not immediately clear in the initial announcement.
Source: Read the original article at NBC